Abstract
Breast cancer is the most common malignant tumors in women. Kinesin family member 3B (KIF3B) is a critical regulator in mitotic progression. The objective of this study was to explore the expression, regulation, and mechanism of KIF3B in 103 cases of breast cancer tissues, 35 metastatic lymph nodes and breast cancer cell lines, including MDA-MB-231, MDA-MB-453, T47D, and MCF-7. The results showed that KIF3B expression was up-regulated in breast cancer tissues and cell lines, and the expression level was correlated with tumor recurrence and lymph node metastasis, while knockdown of KIF3B suppressed cell proliferation, migration, and invasion both in vivo and in vitro. In addition, UALCAN analysis showed that KIF3B expression in breast cancer is increased, and the high expression of KIF3B in breast cancer is associated with poor prognosis. Furthermore, we found that silencing of KIF3B decreased the expression of Dvl2, phospho-GSK-3β, total and nucleus β-catenin, then subsequent down-regulation of Wnt/β-catenin signaling target genes such as CyclinD1, C-myc, MMP-2, MMP-7 and MMP-9 in breast cancer cells. In addition, KIF3B depletion inhibited epithelial mesenchymal transition (EMT) in breast cancer cells. Taken together, our results revealed that KIF3B is up-regulated in breast cancer which is potentially involved in breast cancer progression and metastasis. Silencing KIF3B might suppress the Wnt/β-catenin signaling pathway and EMT in breast cancer cells.
Highlights
Breast cancer is the most common cancer and the leading cause of death in women around the world [1]
We observed that Kinesin family member 3B (KIF3B) expression increased in breast cancer stages 1–3 compared to normal samples (Figure 1B, P < 0.01)
Li et al found that KIF3B is highly expressed in breast cancer, and over-expression of tumor-related Kinesin super family proteins (KIFs) correlates with worse outcome of breast cancer patients by bioinformatic analysis [48]
Summary
Breast cancer is the most common cancer and the leading cause of death in women around the world [1]. Therapeutic management, including surgical resection in combination with hormonal therapy, chemo-radiotherapy and biological therapy, has achieved great progress for this disease. The survival of advanced-stage breast cancer is still very poor [2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
